Alpha‐Synuclein Stimulation of Astrocytes: Potential Role for Neuroinflammation and Neuroprotection

Abstract

Selective loss of neurons, abnormal protein deposition and neuroinflammation are the common pathological features of neurodegenerative diseases, and these features are closely related to one another. In Parkinson′s disease, abnormal aggregation and deposition of α‐synuclein is known as a critical event in pathogenesis of the disease, as well as in other related neurodegenerative disorders, such as dementia with Lewy bodies and multiple system atrophy. Increasing evidence suggests that α‐synuclein aggregates can activate glial cells to induce neuroinflammation. However, how an inflammatory microenvironment is established and maintained by this protein remains unknown. Findings from our recent study suggest that neuronal α‐synuclein can be directly transferred to astrocytes through sequential exocytosis and endocytosis and induce inflammatory responses from astrocytes. Here we discuss potential roles of astrocytes in a cascade of events leading to α‐synuclein‐induced neuroinflammation.

Cited by papers we hold 15

• Astrocyte alterations in α-synucleinopathies · 2025
  Not checked
• Exercise suppresses neuroinflammation for alleviating Alzheimer’s disease · 2023
  No notice
• Neuroinflammation and Parkinson’s Disease—From Neurodegeneration to Therapeutic Opportunities · 2022
  No notice
• The Pathogenesis of Parkinson's Disease: A Complex Interplay Between Astrocytes, Microglia, and T Lymphocytes? · 2021
  No notice
• Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction · 2021
  Not checked
• Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo · 2021
  No notice
• Ablation of polyamine catabolic enzymes provokes Purkinje cell damage, neuroinflammation, and severe ataxia · 2020
  Not checked
• A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson's disease · 2020
  Not checked
• Caffeine and Parkinson’s Disease: Multiple Benefits and Emerging Mechanisms · 2020
  No notice
• Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation · 2018
  No notice
• Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy · 2015
  No notice
• Cellular and Molecular Mediators of Neuroinflammation in the Pathogenesis of Parkinson’s Disease · 2013
  No notice
• Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson’s Disease? · 2013
  No notice
• The prion hypothesis in Parkinson's disease: Braak to the future · 2013
  No notice
• Toll‐like receptor 4 is required for α‐synuclein dependent activation of microglia and astroglia · 2012
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.